Bibliographic Details
| Title: |
EXAMINING LURASIDONE EFFICACY IN SCHIZOPHRENIC PATIENTS WITH COMORBID ALCOHOL AND SUBSTANCE USE DISORDER: A MULTICENTRIC PROSPECTIVE INVESTIGATION. |
| Authors: |
Chiappini, Stefania, Cavallotto, Clara, D'andrea, Giacomo, Di Cesare, Andrea, Mosca, Alessio, Di Carlo, Francesco, Pettorruso, Mauro, Martinotti, Giovanni, Schifano, Fabrizio |
| Source: |
International Journal of Neuropsychopharmacology; 2025 Supplement, Vol. 28, pi91-i92, 2p |
| Subject Terms: |
ALCOHOLISM, TREATMENT effectiveness, DUAL diagnosis, COMORBIDITY, PEOPLE with schizophrenia |
| Abstract: |
Background: Alcohol/Substance Use Disorder (AUD/SUD) among schizophrenic patient represent a common and problematic co-occurrence, with a rate of comorbidity assessed between 40% and 70%, especially in young patients at the onset of their disorder (1-2). Comorbid patients are usually difficult to treat: they show a very low level of compliance, and are frequently exposed to drop-out and lack of efficacy for the available antipsychotic drugs leading to worsened clinical outcomes and increased difficulty in treatment (3-4). Aims & Objectives: to evaluate the effectiveness and safety of the second generation antipsychotic lurasidone in schizophrenic patients comorbid AUD/SUD. Method: In this prospective, multicentric, real-world study, a total of 21 patients (M/F ratio: 14/7; age=34.20 ± 11.81), diagnosed with Schizophrenia and AUD/SUD (6 and 15, respectively) were recruited and treated using lurasidone up to 148mg/day. Evaluations were performed at the baseline (T0) and after 4 weeks (T1) using Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Improvement (CGI-I) scores. Quality of life (Q-LES-Q-SF), alcohol and substance related aggressiveness (Modified Overt Aggression Scale/MOAS), as well as craving for substances (VAS) were assessed. Repeated-measures ANOVA (rm-ANOVA) models were used to estimate the effect of treatment on the aforementioned psychometric scales. Results: Lurasidone was effective in reducing the total burden of psychopathology, as highlighted by the significant reduction of PANSS (F12,1= 8.422; P= 0.013), CGI-S (F11,1= 30.94; P<0.001), MOAS (F12,1= 5.691; P=0.034) total scores. Furthermore, we found a significant reduction of craving intensity/VAS for craving from baseline to T1 (F12,1= 7.112; P= 0.021). The overall impact of Lurasidone has resulted in a significant enhancement of quality of life (Q-LES-Q-SF: F11,1= 5.273; P= 0.042). However, we observed a substantial non-adherence rate to the treatments, with 38% (8 out of 21) of patients discontinuing prior to T1. Among these, 9.5% (2 patients) relapsed into substance use, 9.5% (2 patients) experienced significant side effects, and 19% (4 patients) dropped out for reasons that remain unidentified. Discussion & Conclusion: These preliminary findings underscore the potential utility of Lurasidone for dual disorder patients, targeting not only symptoms within the psychotic spectrum but also behaviours tied to substance and alcohol consumption. The observed high attrition rate is likely due to the inherent nature of the study (outpatients setting, involving subjects with severe dual diagnoses). Overall, pharmacological treatments of dual diagnosis are complex and require personalized approaches considering the heterogeneity of the population. Future research should focus on developing individualized treatment plans and understanding the biological underpinnings of dual diagnosis to create more targeted, effective pharmacological interventions. [ABSTRACT FROM AUTHOR] |
|
Copyright of International Journal of Neuropsychopharmacology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
